Current and future strategies aiming at reducing catecholamine exposure in septic shock - PubMed
4 hours ago
- #vasopressors
- #catecholamine-sparing
- #septic shock
- Norepinephrine is the first-line vasopressor in septic shock, but prolonged catecholamine exposure has adverse effects.
- Early norepinephrine initiation reduces hypotension duration and fluid requirements, but catecholamines can cause dose-dependent cardiac, metabolic, and immunological issues.
- Perfusion-guided strategies, like individualized blood pressure targets and capillary refill time titration, are key to reducing catecholamine use.
- Non-adrenergic vasopressors include vasopressin, which lowers catecholamine exposure and atrial fibrillation risk, and angiotensin II for refractory shock.
- Inhibition of dipeptidyl peptidase 3 (DPP3) is an emerging strategy to preserve angiotensin II.
- Corticosteroids restore vasopressor sensitivity and aid catecholamine weaning.
- Short-acting β1-blockers show hemodynamic promise but need better patient selection.
- Methylene blue targets the nitric oxide pathway for vasodilation.
- Immunomodulatory approaches, like extracellular histone neutralization and polymyxin B hemoperfusion, aim to reduce vasopressor dependency.
- A personalized, multimodal approach with perfusion targets and phenotype-based selection is recommended to minimize adrenergic burden.